Lynch syndrome is a heritable cancer syndrome caused by a heterozygous germline mutation in DNA mismatch repair (MMR) genes. MMR-deficient (dMMR) tumors are particularly sensitive to immune checkpoint inhibitors, an effect attributed to the higher mutation rate in these cancers. However, approximately 15% to 30% of patients with dMMR cancers do not respond to immunotherapy. This report describes 3 patients with Lynch syndrome who each had 2 primary malignancies: 1 with dMMR and a high tumor mutational burden (TMB), and 1 with dMMR but, unexpectedly, a low TMB. Two of these patients received immunotherapy for their TMB-low tumors but experienced no response. We have found that not all Lynch-associated dMMR tumors have a high TMB and propose that tumors with dMMR and TMB discordance may be resistant to immunotherapy. The possibility of dMMR/TMB discordance should be considered, particularly in less-typical Lynch cancers, in which TMB evaluation could guide the use of immune checkpoint inhibitors.
Submitted May 16, 2020; accepted for publication October 27, 2020.
Disclosures: The authors have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.
Funding: Research reported in this article was supported by the NIH under award number P30 CA 008748. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Work for this article was also supported by the American Cancer Society (134065-PF-19-125-01-CSM).
Correspondence: Rona Yaeger, MD, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, 10th Floor, New York, NY 10065. Email: firstname.lastname@example.org
BuckowitzA, KnaebelHP, BennerA, . Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br J Cancer2005;92:1746–1753.
BuckowitzA, KnaebelHP, BennerA, . Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br J Cancer 2005;92:1746–1753.10.1038/sj.bjc.660253415856045)| false
MarabelleA, LeDT, AsciertoPA, . Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol2020;38:1–10.
MarabelleA, LeDT, AsciertoPA, . Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38:1–10.3168255010.1200/JCO.19.02105)| false
GeorgiadisA, DurhamJN, KeeferLA, . Noninvasive detection of microsatellite instability and high tumor mutation burden in cancer patients treated with PD-1 blockade. Clin Cancer Res 2019;25:7024–7034.3150638910.1158/1078-0432.CCR-19-1372)| false
SchrockAB, OuyangC, SandhuJ, . Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol 2019;30:1096–1103.10.1093/annonc/mdz13431038663)| false